Contrasting features of MDR phenotype in leukemias by using two fluorochromes: Implications for clinical practice

Leukemia Research

Volumn 31, Issue 4, 2007, Pages 445-454

  Vasconcelos, Flavia C ^a   Cavalcanti Jr , Geraldo B ^a   Silva, Karina L ^a   de Meis, Ernesto ^b   Kwee, Jolie K ^a   Rumjanek, Vivian M ^c   Maia, Raquel C ^a  

^a Hospital do Câncer 2   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

DiOC2; Flow cytometry; Leukemias; MDR; MRP1; P glycoprotein; Rhodamine 123

Indexed keywords

3,3' DIETHYLOXACARBOCYANINE IODIDE; FLUORESCENT DYE; FLUOROCHROME; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CONTROLLED STUDY; EFFUSION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARBOCYANINES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, PROMYELOCYTIC, ACUTE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHENOTYPE; RHODAMINE 123; TUMOR CELLS, CULTURED;

EID: 33846683203     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.07.016     Document Type: Article

References (50)

1. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Ver Med 53 (2002) 615-627
2. Ross D.D., Karp J.E., Chen T.T., and Doyle L.A. Expression of breast cancer resistance protein in blast cells from patients with acute leukaemia. Blood 96 (2000) 365-368
3. Reed J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7 (1995) 541-546
4. Liston P., Fong W.G., and Korneluk R.G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22 (2003) 8568-8580
5. Hayes J.D., Flanagan J.U., and Jowsey I.R. Glutathione Transferases. Annu Rev Pharmacol Toxicol 45 (2005) 51-88
6. Beck W.T., Grogan T.M., Willmans C.L., et al. Methods to detect P-glycoprotein-associated multidrug resistance in patient's tumors: consensus recommendation. Cancer Res 56 (1996) 3010-3020
7. Kappelmayer J., Simon A., Kiss F., and Hevessy Z. Progress in defining multidrug resistance in leukemia. Expert Rev Mol Diagn 4 (2004) 209-217
8. Loetchutinat C. New insights into the P-glycoprotein-mediated effluxes of rhodamines. Eur J Biochem 270 (2003) 476-485
9. Feller N., Kuiper C.M., Lankelma J., Ruhdal J.K., Scheper R.J., Pinedo H.M., et al. Functional detection of MDR P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 72 (1995) 543-549
10. Broxterman H.J., Sonneveld P., Feller N., Ossenkoppele G.J., Wahrer D.C., Eekman C.A., et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 87 (1996) 4809-4816
11. Marques-Santos L.F., Oliveira J.G., Maia R.C., and Rumjanek V.M. Mitotracker green is a P-glycoprotein substrate. Biosci Rep 23 (2003) 199-212
12. Robey R.W., Medina-Perez W.Y., Nishiyama K., Lahusen T., Miyake K., Litman T., et al. Overexpression of the ATP-binding cassette half-transporter ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7 (2001) 145-152
13. Watanabe T., Tsuge H., Oh-Hara T., Naito M., and Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833 Cyclosporin A and Verapamil on multidrug resistance "in vitro" and "in vivo". Acta Oncol 34 (1995) 235-241
14. Gollapudi S., Kim Ch., Tran B.N., and Sangha S. Probenecide reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL-60Tax and P388/ADR cells. Cancer Chemother Pharmacol 40 (1997) 150-158
15. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., and Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60 (2000) 47-50
16. Rumjanek V.M., Lucena M., Campos M.M., Marques-Silva V.M., and Maia R.C. Multidrug resistance in leukemias: the problem and some approaches to its circumvention. Cienc Cult 46 (1994) 63-69
17. Rumjanek V.M., Trindade G.S., Wagner-Souza K., Melitti-de Oliveira M.C., Marques-Santos L.F., Maia R.C., et al. Multidrug resistance in tumour cells: characterisation of the multidrug resistant cell line K562-Lucena 1. Ann Acad Bras Ci 73 (2001) 57-69
18. Tsuruo T., Iida H., Ohkochi E., Tsukagoshi S., and Sakurai Y. Establishment and properties of a vincristine-resistant human myelogenous leukemia K562. Jpn J Cancer Res 74 (1983) 751-758
19. Maia R.C., Silva E.A.C., Harab R.C., Lucena M., Pires V., and Rumjanek V.M. Sensitivity of vincristine-sensitive K562 and vincristine K562-Lucena 1 cells to anthracyclines and reversal of multidrug resistance. Braz J Med Biol Res 29 (1996) 467-472
20. Maia R.C., Vasconcelos F.C., Harab R.C., Coelho A.M., Dobbin J.A., and Rumjanek V.M. Comparison between anthracyclines and rhodamine-123 accumulation in chronic lymphoid leukemia: effect of cyclosporin A and verapamil. Tumour Biol 19 (1998) 41-51
21. Eijdems E.W., De Haas M., Coco-Martin J.M., Ottenheim C.P., Zaman G.J., Dauwerse H.G., et al. Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer 60 (1995) 676-684
22. Arceci R.J., Stieglitz K., Bras J., Schinkel A., Baas F., and Croop J. Monoclonal antibody to an external epitope of the human mdr1 p-glycoprotein. Cancer Res 15 (1993) 310-317
23. Silva K.L., Vasconcelos F.C., Marques-Santos L.F., Kwee J.K., and Maia R.C. CPT-11 induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res 27 (2003) 243-251
24. Farahat N., van der Plas D., Praxedes M., Morillas R., Matutes E., and Catovisky D. Demonstration of cytoplasmic and nuclear antigens in acute leukaemia using flow cytometry. J Clin Pathol 47 (1994) 843-849
25. Cavalcanti Jr. G.B., Vasconcelos F.C., Pinto G.F., Scheiner M.A., Dobbin J.A., Klumb C.E., et al. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry 61B (2004) 1-8
26. Twentyman P.R., Rhodes T., and Rayner S. A comparison of rhodamine-123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multi-drug resistance phenotypes. Eur J Cancer 30 (1994) 1360-1369
27. 2 (3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 25 (1996) 14-20
28. Huet S., Marie J.-P., Gualde N., and Robert J. Reference method for detection of Pgp mediated multi-drug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry 34 (1998) 248-256
29. Hu X.F., Slater A., Kantharidis P., Rischin D., Juneja S., Rossi R., et al. Altered multi-drug resistence phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93 (1999) 4086-4095
30. - cases. Blood 86 (1995) 2329-2342
31. De Moerloose B., Dhooge C., and Philippe J. Discordance of P-glycoprotein expression and function in acute leukemia. Adv Exp Med Biol 457 (1999) 107-118
32. Giles F.J., Kantarjian H.M., Cortes J., Thomas D.A., Talpaz M., Manshouri T., et al. Multidrug resistance protein expression in chronic myeloid leukemia. Cancer 86 (1999) 805-813
33. Michelutti A., Michieli M., Damiani D., Melli C., Geromin A., Russo D., et al. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica 79 (1994) 200-204
34. Galimberti S., Guerrini F., Palumbo G.A., Consoli U., Fazzi R., Morabito F., et al. Evaluation Of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk Res 28 (2004) 367-372
35. Van der Kolk D.M., de Vries E.G., Muller M., and Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 43 (2002) 685-701
36. Olson D.P., Taylor B.J., La M., Sather H., Reaman G.H., and Ivy S.P. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymphoma 46 (2005) 681-691
37. Casale F., D'Angelo V., Addeo R., Caraglia M., Crisci S., Rondelli R., et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep 12 (2004) 1201-1207
38. Svoboda-Beusan I., Kusec R., Bendelja K., Tudoric-Ghemo I., Jaksic B., Pejsa V., et al. The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica 85 (2000) 1261-1267
39. Tafuri A., Gregorj C., Petrucci M.T., et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 100 (2002) 974-981
40. Dogan A.L., Legrand O., Faussat A.M., Perrot J.Y., and Marie J.P. Evaluation and comparison of MRP1 activity with threee fluorescent dyes and three modulators in leukemic cell lines. Leukemia Res 28 (2004) 619-622
41. Seelig A., and Gatlik-Landwojtowicz E. Inhibitors of multidrug efflux transporters: their membrane and protein interactions. Mini Rev Med Chem 5 (2005) 135-151
42. Depeille P., Cuq P., Mary S., Passagne I., Evrard A., Cupissol D., et al. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol 65 (2004) 897-905
43. Ilmer T., Schaich M., Platzbecker U., et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18 (2004) 401-408
44. Burger H., van Tol H., Boersma A.W.M., Brok M., Wiemer E.A.C., Stoter G., et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP/ABCG2) drug pump. Blood (2004) 2940-2942
45. Takanaga H., Ohnoshi A., Matsuo H., and Sawada Y. Inhibition of vimblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 21 (1998) 1062-1066
46. Deferne S., Van Gelder J., and Augustijns P. Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers; an in-vitro screening. J Pharm Pharmacol 54 (2002) 1213-1219
47. Broxterman H.J., Lankelma J., and Pinedo H.M. How to probe clinical tumor samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 32A (1996) 1024-1033
48. Pallis M., Fisher J., Truran L., Grundy M., Russell N., and Burnett A. Reproducible measurements of AML blast P-glycoprotein function in 2 center analyses. Blood 105 (2005) 1367-1368
49. Hadjeri M. Modulation of P-glycoprotein-mediated multidrug resistant by flavonoid derivatives and analogues. J Med Chem 46 (2003) 2125-2131
50. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11 (2005) 2320-2326